3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
58
Neoplasms
52
Lung Neoplasms
33
Colorectal Neoplasms
28
Carcinoma, Non-Small-Cell Lung
25
Prostatic Neoplasms
22
Melanoma
19
Pancreatic Neoplasms
17
Ovarian Neoplasms
16
Uterine Cervical Neoplasms
14
Sarcoma
12
Multiple Myeloma
12
Lymphoma
11
Glioma
11
Glioblastoma
11
Neoplasm Metastasis
10
Leukemia, Myeloid, Acute
10
Colonic Neoplasms
10
Neoplastic Cells, Circulating
9
Hematologic Neoplasms
9
Lymphoma, Follicular
8
Head and Neck Neoplasms
8
Leukemia
7
Carcinoma, Hepatocellular
7
Brain Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Papillomavirus Infections
6
Myelodysplastic Syndromes
6
Endometrial Neoplasms
6
Disease
6
Interventions
Insulin Glargine
4
Insulin
3
volagidemab
2
Metformin
2
Fulvestrant
2
Alpelisib
2
ziprasidone
1
relacorilant
1
pembrolizumab
1
exemestane
1
dapagliflozin
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Olanzapine
1
Letrozole
1
Insulin Lispro
1
Insulin Aspart
1
Injections
1
DNA, Ribosomal
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hyperglycemia
×
Blood Specimen Collection
×
Clear all
NCT03978702
2022-01-06
IMMUNOPANC
Institut Paoli-Calmettes
Phase NA
Unknown
40 enrolled